Last $51.42 USD
Change Today +0.41 / 0.80%
Volume 72.0K
As of 5:20 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

conmed corp (CNMD) Snapshot

Open
$51.22
Previous Close
$51.01
Day High
$51.45
Day Low
$50.67
52 Week High
02/26/15 - $52.15
52 Week Low
08/14/14 - $35.85
Market Cap
1.4B
Average Volume 10 Days
172.7K
EPS TTM
$1.83
Shares Outstanding
27.6M
EX-Date
03/12/15
P/E TM
28.1x
Dividend
$0.80
Dividend Yield
1.56%
Current Stock Chart for CONMED CORP (CNMD)

conmed corp (CNMD) Related Bloomberg News

View More Bloomberg News

conmed corp (CNMD) Related Businessweek News

No Related Businessweek News Found

conmed corp (CNMD) Details

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures and monitoring in the United States, Canada, the United Kingdom, Japan, Australia, and internationally. The company offers sports medicine products, such as powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bio absorbable implants, and related disposable products and fluid management systems; powered surgical instruments for use in large and small bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; and sports biologics and tissues. It also provides electrosurgical generators, hand pieces, smoke management systems, and accessories for surgical needs; and endomechanical instrumentation products that offer various instruments comprising trocars, clip appliers, scissors, and surgical staplers used in the minimally invasive laparoscopic and gynecological surgery, as well as an uterine manipulator for use in the laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, the company provides mucosal management devices, forceps, scope management accessories, bronchoscopy devices, dilatation, stricture management devices, hemostasis, biliary devices, and polypectomy; pulse oximetry equipment and sensors, ECG electrodes and cables, cardiac defibrillation and pacing pads, and blood pressure cuffs; suction instruments and tubing for use in the operating room; IV products for use in the critical care areas of the hospital; pulmonary monitoring products; and imaging systems for use in the minimally invasive orthopedic and general surgery procedures. The company’s products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

3,500 Employees
Last Reported Date: 02/23/15
Founded in 1970

conmed corp (CNMD) Top Compensated Officers

Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $320.8K
Principal accounting Officer, Executive Vice ...
Total Annual Compensation: $316.9K
General Counsel and Executive Vice President ...
Total Annual Compensation: $290.6K
Compensation as of Fiscal Year 2013.

conmed corp (CNMD) Key Developments

CONMED Corporation Announces Quarterly Cash Dividend, Payable on April 6, 2015

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on April 6, 2015 to all shareholders of record as of March 16, 2015.

CONMED Corporation Presents at Leerink's Global Healthcare Conference, Feb-12-2015 03:30 PM

CONMED Corporation Presents at Leerink's Global Healthcare Conference, Feb-12-2015 03:30 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Curt R. Hartman, Chief Executive Officer, President and Director.

CONMED Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Updates Earnings Guidance for the Full Year 2015

CONMED Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, net sales were $195,003,000 against $203,442,000 a year ago. Income from operations was $17,089,000 against $16,181,000 a year ago. Income before income taxes was $15,550,000 against $14,699,000 a year ago. Net income was $11,339,000 or $0.41 per basic and diluted share against $10,227,000 or $0.36 per diluted share a year ago. Adjusted income from operations was $22,389,000 against $23,203,000 a year ago. EBITDA was $28,657,000 against $28,361,000 a year ago. Adjusted EBITDA was $35,213,000 against $36,874,000 a year ago. Cash provided by operations was very strong at $27.3 million in the fourth quarter. Adjusted net income was $14,731,000 or $0.53 per diluted share against $14,898,000 or $0.53 per diluted share a year ago. Diluted earnings per share on a GAAP basis for the December 2014 quarter improved over the fourth quarter of 2013 due to lower operating expenses, including lower special items. Diluted earnings per share on a GAAP basis for the December 2014 quarter improved over the fourth quarter of 2013 due to lower operating expenses, including lower special items. Adjusting for the special items in both quarterly periods, adjusted diluted EPS was the same in both periods, as lower sales and gross margin in the fourth quarter of 2014 were offset by lower operating costs, a lower tax rate and reduced shares outstanding as compared to the fourth quarter of 2013. For the full year, net sales were $740,055,000 against $762,704,000 a year ago. Income from operations was $52,786,000 against $56,508,000 a year ago. Income before income taxes was $46,675,000 against $50,632,000 a year ago. Net income was $32,192,000 or $1.16 per diluted share against $35,939,000 or $1.28 per diluted share a year ago. Net cash provided by operating activities was $65,176,000 against $80,949,000 a year ago. Purchases of property, plant, and equipment were $15,411,000 against $18,445,000 a year ago. Adjusted income from operations was $82,360,000 against $78,533,000 a year ago. EBITDA was $97,936,000 against $103,816,000 a year ago. Adjusted EBITDA was $132,929,000 against $131,434,000 a year ago. Adjusted net income was $53,378,000 or $1.16 per diluted share against $50,754,000 or $1.28 per diluted share a year ago. GAAP diluted earnings per share declined 9.4% caused by lower sales and higher costs for special items, particularly for those associated with management restructuring, Denver plant consolidation, and shareholder activism. Adjusting for the special items in both years as indicated on the following reconciliation, adjusted earnings per share grew 6.1% due to lower operating costs. The company updated earnings guidance for the year 2015. The company has outlined certain changes in the structure of its commercial organization that management believes will return the company to sales growth in 2015. The company anticipates constant currency sales growth of 1% to 3% for the full year, which will be driven by new product launches and a reorganization of certain aspects of the commercial sales organization in early 2015. As a result, the company expected revenue growth to accelerate in the second half of 2015 compared to the first half of 2015. Company’s prior 2015 guidance contemplated foreign exchange rates as of December 2014. The January 2015 volatility in the currency markets has been significant, and the company has chosen to update 2015 guidance based on currency spot rates as of the close on January 23, 2015. Based on these rates, the updated negative impact of foreign exchange rates versus 2014 is $19 million to revenues and $0.14 to EPS, versus the prior estimates of $6 million and $0.04, respectively. The company anticipated to report sales for 2015 will be in the range of $727 million to $742 million, representing a range of (2%) to 0% versus the prior year. The company continues to expect 2015 constant currency revenue growth of 1% to 3%. In addition, adjusted diluted earnings per share will be in the range of $1.82 to $1.92. The adjusted estimates for the full year 2015 exclude the cost of special items, including the manufacturing consolidation, commercial restructuring and senior management changes which are estimated to be $9.0 million to $11.0 million, net of tax, for 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CNMD:US $51.42 USD +0.41

CNMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ascom Holding AG SFr.16.00 CHF +0.50
Integra LifeSciences Holdings Corp $60.11 USD +0.04
Masimo Corp $31.12 USD +0.68
NuVasive Inc $45.23 USD +0.22
Wright Medical Group Inc $26.32 USD +0.94
View Industry Companies
 

Industry Analysis

CNMD

Industry Average

Valuation CNMD Industry Range
Price/Earnings 44.0x
Price/Sales 1.9x
Price/Book 2.4x
Price/Cash Flow 43.7x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONMED CORP, please visit www.conmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.